查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
脂質代謝治療藥物市場 - 全球市場規模、佔有率、趨勢分析、機會和預測（2019-2029）
市場調查報告書
商品編碼
1391820

脂質代謝治療藥物市場 - 全球市場規模、佔有率、趨勢分析、機會和預測（2019-2029）

Lipid Metabolism Disease Drug Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type; By Distribution Channel; By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格

全球血脂異常治療藥物市場規模預計將以7.1%的年複合成長率大幅擴張，2029年達到244.4億美元。

由於不同地區人們不健康的生活方式導致脂質代謝疾病的盛行率不斷上升，全球脂質代謝疾病治療市場日益受到關注。

領先的策略諮詢和市場研究公司 BlueWeave Consulting 在最近的一項研究中估計，2022 年全球血脂異常藥物市場規模將達到 161.9 億美元。 BlueWeave預測，2023-2029年預測期內，全球血脂異常藥物市場規模將以7.1%的年複合成長率成長，2029年達到244.4億美元。全球血脂異常藥物市場的主要成長動力包括全球醫院和零售藥局等各種應用對這些藥物的需求不斷增加。全球治療代謝紊亂藥物市場由各種營業單位組成，包括公司、營業單位和營業單位，致力於開發和分銷解決代謝疾病各種症狀的藥物。這包括生產胰島素、普蘭林肽和其他抗糖尿病藥物，以及治療甲狀腺亢進的抗甲狀腺藥物。全球副甲狀腺機能亢進症代謝失調藥物市場包括甲狀腺機能低下症、腎上腺、也包含治療甲狀腺疾病的藥物。然而，該市場的歷史軌跡一直受到政府機構和國家政府的嚴格監管，導致治療成本高的批評。由於有義務以折扣價向公共醫療機構和醫生提供藥品，銷售面臨挑戰，導致報酬率下降並影響整體市場擴張。

該報告的詳細分析提供了有關全球血脂異常治療市場的成長潛力、未來趨勢和統計數據的資訊。它還涵蓋了推動市場總規模預測的因素。該報告致力於提供全球血脂異常藥物市場的最新技術趨勢和產業見解，幫助決策者做出策略決策。此外，我們也分析了市場的成長動力、挑戰和競爭力。

目錄

第1章 研究框架

第2章 執行摘要

第3章 全球脂質代謝治療藥物市場洞察

  • 產業價值鏈分析
  • DROC分析
    • 生長促進因子
      • 脂質代謝疾病盛行率增加
      • 不健康生活方式增加
    • 抑制因素
      • 副作用
      • 高成本
    • 機會
      • 老年人口
      • 藥物開發的進展
    • 任務
      • 監管障礙
      • 競爭
  • 科技進步/最新發展
  • 法律規範
  • 波特五力分析

第4章 全球脂質代謝紊亂治療藥物市場概況

  • 市場類型與預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 按類型
      • 成藥
      • 處方藥
    • 按配銷通路
      • 醫院藥房
      • 零售藥房
      • 線上藥房
    • 按地區
      • 北美洲
      • 歐洲
      • 亞太地區
      • 拉丁美洲
      • 中東和非洲

第5章 北美脂質代謝治療藥物市場

  • 市場類型與預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按配銷通路
    • 按國家/地區
      • 美國
      • 加拿大

第6章 歐洲脂質代謝治療藥物市場

  • 市場類型與預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按配銷通路
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 其他歐洲國家

第7章 亞太脂質代謝治療藥物市場

  • 市場類型與預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按配銷通路
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲和紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 越南
      • 其他亞太地區

第8章 拉丁美洲脂質代謝治療藥物市場

  • 市場類型與預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按配銷通路
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 其他拉丁美洲

第9章 中東及非洲脂質代謝紊亂治療藥物市場

  • 市場類型與預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按配銷通路
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • 其他中東/非洲

第10章 競爭形勢

  • 主要企業及其產品列表
  • 全球脂質代謝紊亂治療藥物市場佔有率分析（2022年）
  • 透過管理參數進行競爭基準化分析
  • 主要策略發展（合併、收購、合作夥伴關係等）

第11章新型冠狀冠狀病毒感染疾病（COVID-19）對全球脂質代謝治療藥物市場的影響

第12章公司簡介（公司簡介、財務矩陣、競爭形勢、關鍵人才、主要競爭、聯絡地址、策略展望、SWOT分析）

  • AstraZeneca Plc
  • Boehringer Ingelheim
  • Merck KGaA
  • Novartis AG
  • Takeda Pharmaceutical Co. Ltd
  • Eli Lilly
  • Johnson &Johnson
  • Bayer
  • Pfizer
  • Sanofi
  • 其他主要企業

第13章關鍵戰略建議

第14章調查方法

Product Code: BWC23975

Global Lipid Metabolism Disease Drug Market Size Expands at Significant CAGR of 7.1% to Reach USD 24.44 Billion by 2029.

Global lipid metabolism disease drug market is flourishing because of an increasing focus on the treatment of growing prevalence of lipid metabolism diseases driven by unhealthy lifestyle among people across the regions.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the Global Lipid Metabolism Disease Drug Market size at USD 16.19 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the Global Lipid Metabolism Disease Drug Market size to grow at a significant CAGR of 7.1% reaching a value of USD 24.44 billion by 2029. Major growth drivers for the Global Lipid Metabolism Disease Drug Market include a rising demand for these drugs in various applications, including hospitals and retail pharmacies globally. The Global Lipid Metabolism Disease Drug Market comprises diverse entities, such as companies, proprietorships, and collaborations, committed to developing and distributing medications addressing a range of conditions within metabolic disorders. This involves producing insulin, pramlintide, and other diabetes drugs, along with anti-thyroid medications for hyperthyroidism. The Global Lipid Metabolism Disease Drug Market also encompasses medications for disorders in the pituitary, adrenal, and parathyroid glands, including segments for anti-diabetic and anti-thyroid drugs targeting metabolic diseases like hyperparathyroidism and hypopituitarism. However, the market's historical trajectory is marked by strict regulations from governmental bodies and national governments, leading to criticisms of high treatment costs. Sales challenges have emerged due to obligations to offer medications to public healthcare institutions and physicians at discounted rates, leading to reduced profit margins and impacting the market's overall expansion.

Impact of Geopolitical Tensions on the Global Lipid Metabolism Disease Drug Market

The Global Lipid Metabolism Disease Drug Market has been significantly impacted by intensifying geopolitical tensions in recent times. For instance, the ongoing Russia's war on Ukraine has disrupted supply chains and hindered the production and distribution of pharmaceuticals, affecting the availability of lipid metabolism disease drugs. In addition, the sanctions imposed on Russia by the United States and other countries can limit the movement of essential medical resources, leading to potential shortages. The turmoil has far-reaching consequences on healthcare measures in Ukraine and across the regions, exacerbating the demand for medicines, depleting inventories, and creating logistical obstacles for resupplying critical medical resources. Meanwhile, calls for economic disengagement from Russia by pharmaceutical industry leaders may affect investments and influence healthcare budgets, ultimately affecting patient affordability and the demand for lipid metabolism disease drugs. Beyond the conflict in Ukraine, collaborative research efforts and international partnerships vital for drug development may face strain, potentially slowing down innovations in the field. In essence, these geopolitical tensions introduce uncertainties and challenges across various dimensions of the lipid metabolism disease drug market, emphasizing the need for strategic adaptation and resilience in navigating these complex circumstances.

Despite the current challenges posed by geopolitical tensions, there are potential growth opportunities for the global lipid metabolism disease drug market. The heightened awareness of the vulnerabilities in the pharmaceutical supply chain due to escalating and spreading geopolitical tensions could drive industry stakeholders to invest in more resilient and diversified supply chain models. Innovations in telehealth and digital health solutions may emerge as a response to disruptions in traditional healthcare delivery systems, providing new avenues for patient access and engagement. Also, an increased focus on R&D to address the unique health challenges arising from geopolitical conflicts could lead to the discovery and development of novel therapeutic approaches and drug formulations.

Global Lipid Metabolism Disease Drug Market - By Distribution Channel

Based on distribution channel, the Global Lipid Metabolism Disease Drug Market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies segments. The online pharmacies segment holds the highest share in the global lipid metabolism disease drug market by distribution channel. Online pharmacies offer convenient access to a wide range of medications for lipid metabolism diseases, allowing patients to order prescriptions from the comfort of their homes. The ease of online transactions, doorstep delivery, and the ability to compare prices contribute to the segment's high market share. Additionally, the growing preference for virtual consultations and the expansion of e-commerce platforms further bolster the prominence of online pharmacies in distributing lipid metabolism disease drugs globally.

Global Lipid Metabolism Disease Drug Market - By Region

The in-depth research report on The Global Lipid Metabolism Disease Drug Market covers various country-specific markets across five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Asia Pacific region dominates the global lipid metabolism disease drug market. It can be primarily due to the rising number of teenagers, leading to a higher prevalence of unhealthy lifestyles. This contributes to increased instances of obesity and heart diseases associated with elevated levels of bad cholesterol and unhealthy fats. The region's substantial demand for lipid metabolism disease drugs is a result of these prevalent health challenges, establishing the Asia Pacific as a pivotal market. Moreover, evolving dietary habits and a growing middle class population further underscore the market's importance in addressing lipid metabolism diseases in this region.

Competitive Landscape

Major players operating in the Global Lipid Metabolism Disease Drug market include: AstraZeneca Plc, Boehringer Ingelheim, Merck KGaA, Novartis AG, Takeda Pharmaceutical Co. Ltd, Eli Lilly, Johnson & Johnson, Bayer, Pfizer, and Sanofi. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the Global Lipid Metabolism Disease Drug Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Lipid Metabolism Disease Drug Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Lipid Metabolism Disease Drug Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing prevalence of lipid metabolism diseases
      • 3.2.1.2. Increasing adoption of an unhealthy lifestyle
    • 3.2.2. Restraints
      • 3.2.2.1. Side effects
      • 3.2.2.2. High costs
    • 3.2.3. Opportunities
      • 3.2.3.1. Aging population
      • 3.2.3.2. Advancements in drug development
    • 3.2.4. Challenges
      • 3.2.4.1. Regulatory hurdles
      • 3.2.4.2. Competition
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Lipid Metabolism Disease Drug Market Overview

  • 4.1. Market Type & Forecast, 2019-2029
    • 4.1.1. By Value (USD Billion)
  • 4.2. Market Share and Forecast
    • 4.2.1. By Type
      • 4.2.1.1. OTC
      • 4.2.1.2. Rx Drugs
    • 4.2.2. By Distribution Channel
      • 4.2.2.1. Hospital pharmacies
      • 4.2.2.2. Retail pharmacies
      • 4.2.2.3. Online pharmacies
    • 4.2.3. By Region
      • 4.2.3.1. North America
      • 4.2.3.2. Europe
      • 4.2.3.3. Asia Pacific (APAC)
      • 4.2.3.4. Latin America (LATAM)
      • 4.2.3.5. Middle East and Africa (MEA)

5. North America Lipid Metabolism Disease Drug Market

  • 5.1. Market Type & Forecast, 2019-2029
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Distribution Channel
    • 5.2.3. By Country
      • 5.2.3.1. United States
      • 5.2.3.1.1. By Type
      • 5.2.3.1.2. By Distribution Channel
      • 5.2.3.2. Canada
      • 5.2.3.2.1. By Type
      • 5.2.3.2.2. By Distribution Channel

6. Europe Lipid Metabolism Disease Drug Market

  • 6.1. Market Type & Forecast, 2019-2029
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
      • 6.2.3.1. Germany
      • 6.2.3.1.1. By Type
      • 6.2.3.1.2. By Distribution Channel
      • 6.2.3.2. United Kingdom
      • 6.2.3.2.1. By Type
      • 6.2.3.2.2. By Distribution Channel
      • 6.2.3.3. Italy
      • 6.2.3.3.1. By Type
      • 6.2.3.3.2. By Distribution Channel
      • 6.2.3.4. France
      • 6.2.3.4.1. By Type
      • 6.2.3.4.2. By Distribution Channel
      • 6.2.3.5. Spain
      • 6.2.3.5.1. By Type
      • 6.2.3.5.2. By Distribution Channel
      • 6.2.3.6. Belgium
      • 6.2.3.6.1. By Type
      • 6.2.3.6.2. By Distribution Channel
      • 6.2.3.7. Russia
      • 6.2.3.7.1. By Type
      • 6.2.3.7.2. By Distribution Channel
      • 6.2.3.8. The Netherlands
      • 6.2.3.8.1. By Type
      • 6.2.3.8.2. By Distribution Channel
      • 6.2.3.9. Rest of Europe
      • 6.2.3.9.1. By Type
      • 6.2.3.9.2. By Distribution Channel

7. Asia-Pacific Lipid Metabolism Disease Drug Market

  • 7.1. Market Type & Forecast, 2019-2029
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
      • 7.2.3.1. China
      • 7.2.3.1.1. By Type
      • 7.2.3.1.2. By Distribution Channel
      • 7.2.3.2. India
      • 7.2.3.2.1. By Type
      • 7.2.3.2.2. By Distribution Channel
      • 7.2.3.3. Japan
      • 7.2.3.3.1. By Type
      • 7.2.3.3.2. By Distribution Channel
      • 7.2.3.4. South Korea
      • 7.2.3.4.1. By Type
      • 7.2.3.4.2. By Distribution Channel
      • 7.2.3.5. Australia & New Zealand
      • 7.2.3.5.1. By Type
      • 7.2.3.5.2. By Distribution Channel
      • 7.2.3.6. Indonesia
      • 7.2.3.6.1. By Type
      • 7.2.3.6.2. By Distribution Channel
      • 7.2.3.7. Malaysia
      • 7.2.3.7.1. By Type
      • 7.2.3.7.2. By Distribution Channel
      • 7.2.3.8. Singapore
      • 7.2.3.8.1. By Type
      • 7.2.3.8.2. By Distribution Channel
      • 7.2.3.9. Vietnam
      • 7.2.3.9.1. By Type
      • 7.2.3.9.2. By Distribution Channel
      • 7.2.3.10. Rest of APAC
      • 7.2.3.10.1. By Type
      • 7.2.3.10.2. By Distribution Channel

8. Latin America Lipid Metabolism Disease Drug Market

  • 8.1. Market Type & Forecast, 2019-2029
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
      • 8.2.3.1. Brazil
      • 8.2.3.1.1. By Type
      • 8.2.3.1.2. By Distribution Channel
      • 8.2.3.2. Mexico
      • 8.2.3.2.1. By Type
      • 8.2.3.2.2. By Distribution Channel
      • 8.2.3.3. Argentina
      • 8.2.3.3.1. By Type
      • 8.2.3.3.2. By Distribution Channel
      • 8.2.3.4. Peru
      • 8.2.3.4.1. By Type
      • 8.2.3.4.2. By Distribution Channel
      • 8.2.3.5. Rest of LATAM
      • 8.2.3.5.1. By Type
      • 8.2.3.5.2. By Distribution Channel

9. Middle East and Africa Lipid Metabolism Disease Drug Market

  • 9.1. Market Type & Forecast, 2019-2029
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
      • 9.2.3.1. Saudi Arabia
      • 9.2.3.1.1. By Type
      • 9.2.3.1.2. By Distribution Channel
      • 9.2.3.2. UAE
      • 9.2.3.2.1. By Type
      • 9.2.3.2.2. By Distribution Channel
      • 9.2.3.3. Qatar
      • 9.2.3.3.1. By Type
      • 9.2.3.3.2. By Distribution Channel
      • 9.2.3.4. Kuwait
      • 9.2.3.4.1. By Type
      • 9.2.3.4.2. By Distribution Channel
      • 9.2.3.5. South Africa
      • 9.2.3.5.1. By Type
      • 9.2.3.5.2. By Distribution Channel
      • 9.2.3.6. Nigeria
      • 9.2.3.6.1. By Type
      • 9.2.3.6.2. By Distribution Channel
      • 9.2.3.7. Algeria
      • 9.2.3.7.1. By Type
      • 9.2.3.7.2. By Distribution Channel
      • 9.2.3.8. Rest of MEA
      • 9.2.3.8.1. By Type
      • 9.2.3.8.2. By Distribution Channel

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Lipid Metabolism Disease Drug Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Lipid Metabolism Disease Drug Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. AstraZeneca Plc
  • 12.2. Boehringer Ingelheim
  • 12.3. Merck KGaA
  • 12.4. Novartis AG
  • 12.5. Takeda Pharmaceutical Co. Ltd
  • 12.6. Eli Lilly
  • 12.7. Johnson & Johnson
  • 12.8. Bayer
  • 12.9. Pfizer
  • 12.10. Sanofi
  • 12.11. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations

*Financial information of case of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

List of Figures

  • Figure 1 Global Lipid Metabolism Disease Drug Segmentation
  • Figure 2 Global Lipid Metabolism Disease Drug Market Value Chain Analysis
  • Figure 3 Company Market Share Analysis, 2022
  • Figure 4 Global Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 5 Global Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 6 Global Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 7 Global Lipid Metabolism Disease Drug Market Share, By Region, By Value, 2019-2029
  • Figure 8 North America Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 9 North America Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 10 North America Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value,
  • Figure 11 North America Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
  • Figure 12 United States Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 13 United States Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 14 United States Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 15 Canada Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 16 Canada Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 17 Canada Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 18 Europe Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 19 Europe Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 20 Europe Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 21 Europe Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
  • Figure 22 Germany Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 23 Germany Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 24 Germany Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 25 United Kingdom Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 26 United Kingdom Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 27 United Kingdom Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 28 Italy Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 29 Italy Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 30 Italy Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 31 France Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 32 France Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 33 France Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 34 Spain Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 35 Spain Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 36 Spain Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 37 Belgium Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 38 Belgium Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 39 Belgium Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 40 Russia Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 41 Russia Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 42 Russia Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 43 The Netherlands Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 44 The Netherlands Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 45 The Netherlands Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 46 Rest of Europe Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 47 Rest of Europe Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 48 Rest of Europe Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 49 Asia-Pacific Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 50 Asia-Pacific Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 51 Asia-Pacific Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 52 Asia-Pacific Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
  • Figure 53 China Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 54 China Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 55 China Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 56 India Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 57 India Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 58 India Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 59 Japan Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 60 Japan Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 61 Japan Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 62 South Korea Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 63 South Korea Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 64 South Korea Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 65 Australia & New Zealand Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 66 Australia & New Zealand Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 67 Australia & New Zealand Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 68 Indonesia Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 69 Indonesia Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 70 Indonesia Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 71 Malaysia Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 72 Malaysia Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 73 Malaysia Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 74 Singapore Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 75 Singapore Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 76 Singapore Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 77 Vietnam Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 78 Vietnam Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 79 Vietnam Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 80 Rest of APAC Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 81 Rest of APAC Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 82 Rest of APAC Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 83 Latin America Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 84 Latin America Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 85 Latin America Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 86 Latin America Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
  • Figure 87 Brazil Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 88 Brazil Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 89 Brazil Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 90 Mexico Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 91 Mexico Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 92 Mexico Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 93 Argentina Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 94 Argentina Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 95 Argentina Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 96 Peru Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 97 Peru Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 98 Peru Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 99 Rest of LATAM Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 100 Rest of LATAM Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 101 Rest of LATAM Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 102 Middle East & Africa Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 103 Middle East & Africa Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 104 Middle East & Africa Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 105 Middle East & Africa Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
  • Figure 106 Saudi Arabia Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 107 Saudi Arabia Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 108 Saudi Arabia Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 109 UAE Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 110 UAE Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 111 UAE Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 112 Qatar Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 113 Qatar Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 114 Qatar Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 115 Kuwait Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 116 Kuwait Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 117 Kuwait Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 118 South Africa Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 119 South Africa Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 120 South Africa Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 121 Nigeria Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 122 Nigeria Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 123 Nigeria Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 124 Algeria Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 125 Algeria Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 126 Algeria Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Figure 127 Rest of MEA Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Figure 128 Rest of MEA Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Figure 129 Rest of MEA Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029

List of Tables

  • Table 1 Global Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 2 Global Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 3 Global Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 4 Global Lipid Metabolism Disease Drug Market Share, By Region, By Value, 2019-2029
  • Table 5 North America Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 6 North America Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 7 North America Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 8 North America Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
  • Table 9 United States Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 10 United States Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 11 United States Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 12 Canada Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 13 Canada Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 14 Canada Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 15 Europe Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 16 Europe Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 17 Europe Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 18 Europe Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
  • Table 19 Germany Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 20 Germany Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 21 Germany Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 22 United Kingdom Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 23 United Kingdom Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 24 United Kingdom Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 25 Italy Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 26 Italy Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 27 Italy Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 28 France Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 29 France Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 30 France Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 31 Spain Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 32 Spain Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 33 Spain Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 34 Belgium Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 35 Belgium Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 36 Belgium Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 37 Russia Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 38 Russia Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 39 Russia Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 40 The Netherlands Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 41 The Netherlands Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 42 The Netherlands Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 43 Rest of Europe Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 44 Rest of Europe Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 45 Rest of Europe Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 46 Asia-Pacific Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 47 Asia-Pacific Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 48 Asia-Pacific Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 49 Asia-Pacific Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
  • Table 50 China Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 51 China Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 52 China Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 53 India Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 54 India Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 55 India Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 56 Japan Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 57 Japan Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 58 Japan Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 59 South Korea Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 60 South Korea Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 61 South Korea Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 62 Australia & New Zealand Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 63 Australia & New Zealand Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 64 Australia & New Zealand Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 65 Indonesia Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 66 Indonesia Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 67 Indonesia Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 68 Malaysia Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 69 Malaysia Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 70 Malaysia Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 71 Singapore Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 72 Singapore Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 73 Singapore Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 74 Vietnam Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 75 Vietnam Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 76 Vietnam Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 77 Rest of APAC Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 78 Rest of APAC Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 79 Rest of APAC Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 80 Latin America Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 81 Latin America Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 82 Latin America Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 83 Latin America Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
  • Table 84 Brazil Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 85 Brazil Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 86 Brazil Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 87 Mexico Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 88 Mexico Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 89 Mexico Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 90 Argentina Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 91 Argentina Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 92 Argentina Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 93 Peru Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 94 Peru Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 95 Peru Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 96 Rest of LATAM Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 97 Rest of LATAM Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 98 Rest of LATAM Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 99 Middle East & Africa Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 100 Middle East & Africa Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 101 Middle East & Africa Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 102 Middle East & Africa Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
  • Table 103 Saudi Arabia Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 104 Saudi Arabia Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 105 Saudi Arabia Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 106 UAE Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 107 UAE Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 108 UAE Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 109 Qatar Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 110 Qatar Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 111 Qatar Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 112 Kuwait Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 113 Kuwait Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 114 Kuwait Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 115 South Africa Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 116 South Africa Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 117 South Africa Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 118 Nigeria Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 119 Nigeria Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 120 Nigeria Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 121 Algeria Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 122 Algeria Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 123 Algeria Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
  • Table 124 Rest of MEA Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
  • Table 125 Rest of MEA Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
  • Table 126 Rest of MEA Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029Table 207 Alnylam Pharmaceuticals Company Overview
  • Table 126 AstraZeneca Plc Company Overview
  • Table 127 AstraZeneca Plc Financial Overview
  • Table 128 Boehringer Ingelheim Company Overview
  • Table 129 Boehringer Ingelheim Financial Overview
  • Table 130 Merck KGaA Company Overview
  • Table 131 Merck KGaA Financial Overview
  • Table 132 Novartis AG Company Overview
  • Table 133 Novartis AG Financial Overview
  • Table 134 Takeda Pharmaceutical Co. Ltd Company Overview
  • Table 135 Takeda Pharmaceutical Co. Ltd Financial Overview
  • Table 136 Eli Lilly Company Overview
  • Table 137 Eli Lilly Financial Overview
  • Table 138 Johnson & Johnson Company Overview
  • Table 139 Johnson & Johnson Financial Overview
  • Table 140 Bayer Company Overview
  • Table 141 Bayer Financial Overview
  • Table 142 Pfizer Company Overview
  • Table 143 Pfizer Financial Overview
  • Table 144 Sanofi Company Overview
  • Table 145 Sanofi Financial Overview